The critics of Bionano (NASDAQ:BNGO) stock are ignoring and/or severely underestimating developments involving its DNA mapping tool, Saphyr. Source: Natali_ Mis/ShutterStock.com Specifically, there is ...
Bionano Genomics BNGO just pulled back the curtain on its fourth-quarter results, and the message is clear: the company is getting leaner while its technology goes deeper into the clinical mainstream.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results